INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
NEW HAVEN, Conn. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
View HTML
Toggle Summary Achillion Appoints Brian Di Donato as Chief Financial Officer
NEW HAVEN, Conn. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato
View HTML
Toggle Summary Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
Nicole Vitullo Brings Public Company Investment and Leadership Expertise as the next Chair of Achillion Board of Directors NEW HAVEN, Conn. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the
View HTML
Toggle Summary Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update
ACH-4471, First Generation Oral factor D Inhibitor - Proof of Concept Validated in both PNH as Monotherapy and in Combination w/C5 Inhibitor  - Proof of Mechanism Validated in C3G, End of Phase 2 Meeting Targeted for 4Q 2019 ACH-5228, Next Generation Oral factor D Inhibitor - Data Demonstrate 3x to
View HTML
Toggle Summary Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
NEW HAVEN, Conn. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the
View HTML
Toggle Summary Achillion Reports Third Quarter 2018 Financial Results
- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 million –  - Mary Kay Fenton to step down as CFO at year-end 2018 - NEW HAVEN, Conn.
View HTML
Toggle Summary Achillion to Present at the Leerink Partners Roundtable Series
NEW HAVEN, Conn. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 ,
View HTML
Toggle Summary Achillion Appoints Paul Firuta Chief Operating Officer
NEW HAVEN, Conn. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and Chief Operating Officer effective immediately. Mr. Firuta, with 27 years of experience successfully
View HTML
Toggle Summary Achillion to Present at the Baird 2018 Global Healthcare Conference
NEW HAVEN, Conn. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6th, 2018 , at 9:05 a.m.
View HTML